8-K: Hepion Licenses Novel ctRNA Assay for Early Liver Cancer Detection

Hepion Pharmaceuticals secures a license for a novel circulating tumor RNA biomarker assay from Cirna Diagnostics to enhance early diagnosis of hepatocellular carcinoma.

Summary

• Hepion Pharmaceuticals, Inc. entered into an intellectual property license agreement with Cirna Diagnostics, LLC on February 25, 2026.
• The agreement grants Hepion rights to a novel biomarker assay that detects mutant circulating tumor RNA (ctRNA) for early diagnosis of hepatocellular carcinoma (HCC) in high-risk patients.
• Hepion will pay an upfront fee of $50,000, certain patent expenses, up to $2,350,000 in milestone payments, up to $4,500,000 in sales milestone payments, and a low single-digit royalty on net sales.
• This in-licensing deal reflects Hepion's strategic shift, under CEO Kaouthar Lbiati, to advance clinically proven liquid biopsy tests, complementing its existing mSEPT9 PCR-based assay.
• The ctRNA platform is a blood-based test designed for earlier detection and improved specificity compared to DNA-based approaches, with potential applications beyond liver cancer in other solid tumor types.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive strategic development, expanding Hepion's pipeline with a promising technology in a high-growth market, but acknowledges the inherent risks of early-stage biotech, including significant future financing needs and execution challenges.

Positives

• Acquisition of a novel, non-invasive ctRNA biomarker assay addresses a significant unmet need in early HCC diagnosis, as current surveillance methods miss up to 75% of early-stage cancers.
• The ctRNA platform offers earlier detection and improved specificity by capturing actively expressed tumor signatures, unlike DNA-based methods.
• The technology is disease-agnostic, with direct applications in lung, breast, pancreatic, and fusion-driven cancers, and potential utility across the full arc of clinical management.
• The in-licensing agreement advances Hepion's strategic evolution towards precision diagnostics and strengthens its pipeline alongside the mSEPT9 PCR-based assay.
• The global liquid biopsy market is valued at $10 billion and projected to reach nearly $9 billion in the U.S. alone by 2035, indicating substantial commercial opportunity.

Risks

• Substantial competition in the diagnostics market.
• The company's ability to continue as a going concern.
• Need for additional financing to support operations and development.
• Uncertainties related to patent protection and potential litigation.
• Risks associated with delays in development, regulatory approval, or commercialization.
• Uncertainties regarding government or third-party payer reimbursement for diagnostic tests.
• Limited sales and marketing efforts and dependence upon third parties for commercialization.
• Risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.

Future Outlook

Hepion Pharmaceuticals aims to prepare both the ctRNA platform and the mSEPT9 PCR-based assay for commercialization, with a roadmap including CLIA lab partnerships, pharma companion diagnostics collaborations, and co-development/co-commercialization agreements. The company believes these assays will significantly improve early detection and surveillance of HCC, potentially extending to other solid tumor types.

Management Comments

• "Our diagnostic tests are designed to catch tumors early in high-risk patients and minimize later-stage diagnoses where prognosis is grim, thereby significantly improving the probability of survival in high-risk patients." Dr. Kaouthar Lbiati, Hepion CEO.
• "Our pathway toward regulatory submission and commercialization of the ctRNA platform will present numerous opportunities for CLIA lab partnerships initially, pharma companion diagnostics collaborations in the midterm, and co-development/co-commercialization agreements through the platforms lifecycle. We believe these opportunities will enhance the value of our ctRNA asset and the broader portfolio of biomarkers, benefiting both patients and shareholders." Dr. Kaouthar Lbiati, Hepion CEO.
• "Circulating tumor RNA liquid biopsy offers a more abundant signal and detects mutations and splicing variants that are invisible to DNA-based tests." Dr. Aejaz Sayeed, Chief Scientific Officer at Cirna Diagnostics.

Industry Context

StockSavvy.ai notes that this strategic move by Hepion Pharmaceuticals aligns with the broader industry trend of increasing investment and innovation in the liquid biopsy market, which is experiencing significant growth due to the demand for less invasive and earlier cancer detection methods. The focus on HCC, a highly lethal cancer, positions Hepion in a critical area of unmet medical need, competing with other diagnostic companies developing advanced cancer screening technologies.

Comparison to Industry Standards

• The ctRNA platform is presented as a 'next-generation approach' to liquid biopsy, offering advantages over DNA-based methods by capturing actively expressed tumor signatures for earlier detection and improved specificity.
• Current HCC surveillance methods are noted to miss up to 75% of early-stage cancers, highlighting the potential for Hepion's assays to significantly outperform existing standards.
• The global liquid biopsy market, currently valued at $10 billion and projected to reach nearly $9 billion in the U.S. alone by 2035, indicates a robust and expanding market, suggesting Hepion is entering a high-growth segment comparable to other innovative diagnostic companies.

Related Party Transactions

• Timothy Block, PhD, a co-inventor of the ctRNA platform, is a member of Hepion's Board of Directors.

Stakeholder Impact

• **Shareholders:** Potential for increased company value through pipeline expansion and entry into a high-growth market, but also exposure to significant development and commercialization risks and future dilution from financing needs.
• **Patients:** Improved probability of survival for high-risk HCC patients through earlier and more accurate diagnosis.
• **Healthcare Providers:** Access to next-generation, non-invasive diagnostic tools for HCC surveillance and early detection.
• **Cirna Diagnostics, LLC:** Financial benefits from upfront, milestone, sales milestone, and royalty payments.

Next Steps

• Prepare the ctRNA platform for regulatory submission and commercialization.
• Pursue CLIA lab partnerships, pharma companion diagnostics collaborations, and co-development/co-commercialization agreements.
• Continue advancing the mSEPT9 PCR-based assay for commercialization.

Key Dates

Recommendation

This filing represents a significant strategic pivot and pipeline enhancement for Hepion, addressing a critical unmet medical need in a growing market. While the potential for the ctRNA assay is substantial, the company faces considerable execution risks, including regulatory hurdles, intense competition, and a stated need for additional financing. A 'hold' recommendation reflects the positive long-term outlook from this strategic move, balanced against the inherent risks and costs associated with developing and commercializing novel diagnostic technologies in the biotech sector.

Keywords

Hepatocellular Carcinoma, HCC, Liquid Biopsy, ctRNA, Circulating Tumor RNA, Biomarker Assay, Early Cancer Detection, Precision Diagnostics, Liver Cancer, Oncology